Literature DB >> 23077482

Systems analysis of a mouse xenograft model reveals annexin A1 as a regulator of gene expression in tumor stroma.

Ming Yi1.   

Abstract

Annexin A1 is a multi functional molecule which is involved in inflammation, innate and adaptive immune systems, tumor progression and metastasis. We have previously showed the impaired tumor growth, metastasis, angiogenesis and wound healing in annexin A1 knockout mice. While tumor is a piece of heterogeneous mass including not only malignant tumor cells but also the stroma, the importance of the tumor stroma for tumor progression and metastasis is becoming increasingly clear. The tumor stroma is comprised by various components including extracellular matrix and non-malignant cells in the tumor, such as endothelial cells, fibroblasts, immune cells, inflammatory cells. Based on our previous finding of pro-angiogenic functions for annexin A1 in vascular endothelial cell sprouting, wound healing, tumor growth and metastasis, and the previously known properties for annexin A1 in immune cells and inflammation, this study hypothesized that annexin A1 is a key functional player in tumor development, linking the various components in tumor stroma by its actions in endothelial cells and immune cells. Using systems analysis programs commercially available, this paper further compared the gene expression between tumors from annexin A1 wild type mice and annexin A1 knockout mice and found a list of genes that significantly changed in the tumor stroma that lacked annexin A1. This revealed annexin A1 to be an effective regulator in tumor stroma and suggested a mechanism that annexin A1 affects tumor development and metastasis through interaction with the various components in the microenvironment surrounding the tumor cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077482      PMCID: PMC3471933          DOI: 10.1371/journal.pone.0043551

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

We recently showed the pro-angiogenic functions in tumor development for annexin A1 [1] which was previously known as an inflammatory protein. Tumor growth and metastasis were significantly decreased when tumors grew in host animals unable to express annexin A1 [1]. While tumor is a piece of heterogeneous mass including not only malignant tumor cells but also the stroma, the importance of the tumor stroma for tumor progression and metastasis is becoming increasingly clear. The tumor stroma is comprised by extracellular matrix and non-malignant cells in the tumor, which include endothelial cells, fibroblasts, immune cells, inflammatory cells such as macrophages [2], [3]. Although the tumor stroma has been sought after as a therapeutic target, the mechanisms for how the interaction of various components in the complex tumor stroma contributes to the tumor development are still poorly understood. Based on our recent finding of pro-angiogenic functions for annexin A1 in vascular endothelial cell sprouting, wound healing, and tumor growth and metastasis [1], and the previously known properties for annexin A1 in immune cells and inflammation [4], this study hypothesized that annexin A1 is a key functional player in tumor development, linking the various components in tumor stroma by its actions in endothelial cells and immune cells. Here, we used systems biology approach to analyze the tumors in whole animal models on the background of absence or presence of annexin A1 to show the global effects of annexin A1 on tumor stroma. It is impossible to study tumor stroma with isolated proteins, cultured cell homogenates or even whole live cells. Tumor cells in culture lack the microenvironment or the stroma provided by the body that hosts the tumor. Our whole animal models offered significant advantages over any other conditions. Of particular importance our systems based approaches provided thorough analysis and generated interesting and thought-provoking results.

Methods

Mice and Tumor Models

Annexin A1 knockout homozygous and congenic wildtype counterpart homozygous mice, tumor cell culture, B16 melanoma cell line and subcutaneous tumor model were as described previously [1]. Briefly, to grow the xenograft tumors on the mice, B16 melanoma cells were grown in continuous culture for no more than 3 consecutive passages, the actively growing cells were then trypsinized (0.25% trypsin/1 mM Na-EDTA; Gibco/BRL), resuspended in DMEM (Dulbecco modified Eagle medium), counted, and injected subcutaneously into the right flanks of the mice at 5×106 cells in 200 µL DMEM for each mouse. The B16 cell line was an established cell line and was obtained and used in Dr. Schnitzer's lab in Sidney Kimmel Cancer Center and Proteogenomics Research Institute for Systems Medicine, San Diego, California, United States of America, and the B16 cell line related work was previously published [1].

Systems Analysis and Gene Microarray

The GeneChip mouse genome 430 2.0 array (Affymetrix) was used to analyze tumors from annexin A1 knockout or wildtype mice as described previously [1]. The dataset containing genes that are differentially expressed in the tumors from annexin A1 knockout mice and wildtype mice was analyzed using Genomatix software (Genomatix Software) and Gene Ontology database [5] and IPA software (Ingenuity Systems). Study Approval. This study was approved by Sidney Kimmel Cancer Center and Proteogenomics Research Institute for Systems Medicine, San Diego, California, United States of America.

Results

The tumors were grown in both annexin A1 null and wild type mice using B16 melanoma cells as described previously [1]. In this system, only the stroma in the tumor differs because the non-tumor cells are from the host body with or without annexin A1. From the raw data obtained previously [1] using mouse whole genome microarrays to run tumor samples from annexin A1 knockout and wildtype mice, this study performed thorough systems analysis. The gene expression levels in the whole tumors from annexin A1 knockout and wildtype mice were analyzed to obtain differential expression profiling (Fig. 1). For each gene probe in the mouse genome, the expression levels of the gene probe in tumors from annexin A1 null mice (ko) and from annexin A1 wild-type mice (wt) were compared and expressed as ratio of ko over wt, which reflects from three independent repeat experiments. In tumors from annexin A1 null mice, those genes with highest values were over-expressed (red colored region in Fig. 1) while those genes with lowest values were under-expressed (blue colored region in Fig. 1). The majority of the genome was expressed at similar extent in tumors from annexin A1 null and wild-type mice with the expression ratio values approaching one or the logarithm of the expression ratio values close to zero (Fig. 1). Total about 1000 genes with either highest or lowest ratio values were identified as significantly changed genes in the tumors.
Figure 1

Gene differential expression profile of tumors from annexin A1 knockout and wild type mice.

B16 melanoma cells were implanted in annexin A1 knockout and wild type mice to grow up tumors. Whole tumors were analyzed using mouse whole genome microarray, in which for each gene, one or more than one probeset(s) were spotted for the gene. For each probeset on the microarray, the difference in gene expression between tumors from annexin A1 knockout mice and from wild type mice was expressed as log 2 ratio of the gene expression level in annexin A1 knockout (ko) over the gene expression level in wild type (wt).

Gene differential expression profile of tumors from annexin A1 knockout and wild type mice.

B16 melanoma cells were implanted in annexin A1 knockout and wild type mice to grow up tumors. Whole tumors were analyzed using mouse whole genome microarray, in which for each gene, one or more than one probeset(s) were spotted for the gene. For each probeset on the microarray, the difference in gene expression between tumors from annexin A1 knockout mice and from wild type mice was expressed as log 2 ratio of the gene expression level in annexin A1 knockout (ko) over the gene expression level in wild type (wt). We then analyzed this list of significantly changed genes/proteins in a systems biology approach with Genomatix and IPA software to reveal the functional connection with annexin A1. The data were examined in terms of biological processes category, which are the Gene Ontology (GO) structured networks of defined terms to describe gene product attributes. The data were statistically analyzed and expressed as the z-score of a term to check for over- or under- represented groups of genes. Integrated statistical rating allows for the identification and selection of clusters of functionally related genes. All the biological processes in the GO database were obtained from top of the hierarchial tree to further mining down of subcategories of each branch levels by levels. The top most general biological processes are shown with their z-scores (Fig. 2). Interestingly, most of the biological processes were positively enriched, suggesting that annexin A1 may act as a global regulator which affects many biological processes and some of these processes may balance each other to result in minimum changes, which could contribute to the annexin A1 knockout mice appearing normal overall. The z-score of a term shows whether a certain gene, or group of genes, is over- or under-represented in the set of the genes being analyzed. Among the total 22 categories, the immune system process was most significantly over-represented (z-score, 20.63). This indicates that a group of genes, which are functionally related to immune system, were over-represented in the list of the differentially expressed genes identified above. This is consistent with the previously known functions of annexin A1 in immune system [4], thus the other genes related to immune system changed their expression levels in the tumors grown in the host microenvironment where annexin A1 was knocked out. Breakdown of this immune system process into its subcategories is shown in detail with the biological processes down levels by levels (Fig.S1) and shown in summary with representative biological processes (Fig. 3). The process of immune response to tumor cell was not much different between tumors in annexin A1 ko and wild-type conditions, consistent with our notion that it was the tumor stroma that made the tumor development significantly different in annexin A1 negative condition. Among the immune cells that were present in tumor stroma, T cell related processes stood out, which is consistent with the recently identified effects of annexin A1 on T cell functions [6].
Figure 2

Biological process.

The list of significantly changed genes was analyzed with Genomatix software and examined in terms of biological processes in Gene Ontology database and expressed as the Z score of a term for each biological process within the category. The higher value of Z score means more genes in that function of biological process were affected in this experiment, thus this biological process was over-represented. The Z scores for all the biological processes in top most general level of Gene Ontology structural networks of hierarchial tree of categories of biological process were shown here.

Figure 3

Immune system process.

Mining down in Gene Ontology structural networks of hierarchial tree of categories of biological process, from top most general biological processes in Figure 2, the most over-represented immune system process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S1 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the immune system process.

Biological process.

The list of significantly changed genes was analyzed with Genomatix software and examined in terms of biological processes in Gene Ontology database and expressed as the Z score of a term for each biological process within the category. The higher value of Z score means more genes in that function of biological process were affected in this experiment, thus this biological process was over-represented. The Z scores for all the biological processes in top most general level of Gene Ontology structural networks of hierarchial tree of categories of biological process were shown here.

Immune system process.

Mining down in Gene Ontology structural networks of hierarchial tree of categories of biological process, from top most general biological processes in Figure 2, the most over-represented immune system process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S1 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the immune system process. Besides immune system process, other significantly over-represented general biological processes include cell killing, cellular process, biological adhesion, multicellular organismal process, developmental process, locomotion, response to stimulus, biological regulation, positive regulation of biological process, negative regulation of biological process, and regulation of biological process (Fig. 2). All of these processes were further mined down to their subcategories and the summary of the analyses were shown (Figs. 4, 5, 6, and 7) with the detailed analyses for each subcategory shown in supplementary information section (Figs.S2, S3, S4, S5, S6, S7, and S8). Mining down in the cell killing process (Fig. 4A), again, the category T cell mediated cytotoxicity was over-represented. Further highlighting the involvement of the immune, inflammatory components in the tumor stroma, the cellular process brought out the enriched process of macrophage differentiation (Fig. 5). Biological adhesion process (Fig. 4B) showed an over-representation of leukocyte adhesion, in line with the interaction between extracellular matrix and infiltrated non-tumor cells in tumor stroma. The process of tumor necrosis factor production was over-represented (Fig. 4C), consistent with our previous findings of increased necrosis in tumors grown in annexin A1 null mice [1], the change in tumor necrosis factor production may contribute to the amount of necrosis in tumors. As shown previously [1], angiogenesis was over-represented (Fig. 4D), the process involving endothelial cells in tumor stroma. The locomotion process (Fig. 4E) indicated an over-representation of leukocyte chemotaxis and neutrophil chemotaxis, both processes involving immune cells in tumor stroma. Again in the response to stimulus process (Fig. 6), the categories related to inflammatory response were significantly over-represented. It is noteworthy that the acute inflammatory response was also over-represented but not the chronic inflammatory response. Finally, biological processes related to regulation (Fig. 7), with overlapping subcategories showed a general over-representation of regulation for those over-represented biological processes discussed above. The positive regulation of biological process was more over-represented than the negative regulation of biological process.
Figure 4

General biological processes other than immune system process.

(A) Cell killing. (B) Biological adhesion. (C) Multicellular organismal process. (D) Developmental process. (E) Locomotion. Similarly as Figure 3, the most general processes were further mining down levels by levels into its subcategories with all biological processes in each level shown in Figures S2, S3, S4, S5, and S6 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in these biological processes.

Figure 5

Cellular process.

Similarly, from Figure 2, the cellular process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S7 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the cellular process.

Figure 6

Response to stimulus.

From Figure 2, the response to stimulus process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S8 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the response to stimulus process.

Figure 7

General biological processes other than immune system process.

(A) Biological regulation. (B) Positive regulation of biological process. (C) Negative regulation of biological process. (D) Regulation of biological process. From Figure 2, these biological processes were further mining down into their subcategories.

General biological processes other than immune system process.

(A) Cell killing. (B) Biological adhesion. (C) Multicellular organismal process. (D) Developmental process. (E) Locomotion. Similarly as Figure 3, the most general processes were further mining down levels by levels into its subcategories with all biological processes in each level shown in Figures S2, S3, S4, S5, and S6 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in these biological processes.

Cellular process.

Similarly, from Figure 2, the cellular process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S7 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the cellular process.

Response to stimulus.

From Figure 2, the response to stimulus process was further mining down levels by levels into its subcategories with all biological processes in each level shown in Figure S8 and from each level, the over-represented biological processes are summarized here. Each color represents each level in the order from top to bottom as mining down the levels from top level of the hierarchial tree in the response to stimulus process. (A) Biological regulation. (B) Positive regulation of biological process. (C) Negative regulation of biological process. (D) Regulation of biological process. From Figure 2, these biological processes were further mining down into their subcategories. Furthermore, we identified the molecules that were responsible for those over-represented biological processes to reveal an interactome in tumor stroma with annexin A1 being a key functional player. Using Genomatix and IPA software, we obtained lists of biological processes or functions with a list of molecules in each process or function. We combined the lists of molecules from the processes or functions that involve various components in tumor stroma to generate the list of molecules that comprises the tumor stroma interactome which interacts with annexin A1 (Table 1). These molecules showed most significant changes, either most down-regulated (log2 (ko/wt)<−0.999), or most up-regulated (log2 (ko/wt)>0.956), in the tumor stroma that lacked annexin A1. Based on the current literature data so far, most of the molecules on this list formed an interaction network built by IPA software (Fig. 8), of which, the interaction between annexin A1 and integrin beta 2 and the interaction between annexin A1 and vascular cell adhesion molecule 1 were identified based on current data. This interaction may occur in cell plasma membrane (Fig. 9). The expression ratio of integrin beta 2 in tumors from annexin A1 ko versus wt was 0.378 (Table 1), so the integrin beta 2 was down-regulated in the absence of annexin A1; and the vascular cell adhesion molecule 1 was even down-regulated (ratio of ko versus wt was 0.214).
Table 1

Tumor Stroma Interactome for Annexin A1.

Gene SymbolGene Name/Gene TitleEntrez Geneko/wt
Igh-6immunoglobulin heavy chain 6 (heavy chain of IgM)160190.065
Tgfbitransforming growth factor, beta induced218100.108
H2-Eb1histocompatibility 2, class II antigen E beta149690.124
Cd74CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)161490.143
Ptprcprotein tyrosine phosphatase, receptor type, C192640.143
Mmp13matrix metallopeptidase 13173860.147
Pla2g7phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)272260.164
H2-Aahistocompatibility 2, class II antigen A, alpha149600.169
Cxcl13chemokine (C-X-C motif) ligand 13559850.170
H2-Ab1histocompatibility 2, class II antigen A, beta 1149610.199
Fpr-rs2formyl peptide receptor, related sequence 2142890.203
Mmp3matrix metallopeptidase 3173920.206
Sfrp2secreted frizzled-related protein 2203190.206
Vcam1vascular cell adhesion molecule 1223290.214
Tgm2transglutaminase 2, C polypeptide218170.227
H2-Q7histocompatibility 2, Q region locus 71000440200.227
Ly6alymphocyte antigen 6 complex, locus A1104540.230
Ly86lymphocyte antigen 86170840.234
Igjimmunoglobulin joining chain160690.237
Fcgr1Fc receptor, IgG, high affinity I141290.238
H2-DMahistocompatibility 2, class II, locus DMa149980.241
C1qbcomplement component 1, q subcomponent, beta polypeptide122600.244
C1qccomplement component 1, q subcomponent, C chain122620.250
Hckhemopoietic cell kinase151620.256
Saa3serum amyloid A 3202100.257
Bcl2a1dB-cell leukemia/lymphoma 2 related protein A1d120470.258
Bcl2a1aB-cell leukemia/lymphoma 2 related protein A1a120440.258
Ccr5chemokine (C-C motif) receptor 5127740.261
Col1a1procollagen, type I, alpha 1128420.268
Cxcl16chemokine (C-X-C motif) ligand 16661020.271
Il2rginterleukin 2 receptor, gamma chain161860.281
C1qacomplement component 1, q subcomponent, alpha polypeptide122590.288
Cxcl9chemokine (C-X-C motif) ligand 9173290.290
Ccl8chemokine (C-C motif) ligand 81000485540.290
Lpllipoprotein lipase169560.291
Klra17killer cell lectin-like receptor, subfamily A, member 171707330.291
Egr1early growth response 1136530.296
Csf1rcolony stimulating factor 1 receptor129780.297
Ctsscathepsin S130400.300
Itgaxintegrin alpha X164110.301
Coro1acoronin, actin binding protein 1A127210.301
Clec7aC-type lectin domain family 7, member a566440.301
Fcer1gFc receptor, IgE, high affinity I, gamma polypeptide141270.308
Lcp2lymphocyte cytosolic protein 2168220.311
Tnctenascin C219230.319
Irf8interferon regulatory factor 8159000.319
Srgnserglycin190730.322
Serpina3nserine (or cysteine) peptidase inhibitor, clade A, member 3N207160.325
TyrobpTYRO protein tyrosine kinase binding protein221770.327
Ccl3chemokine (C-C motif) ligand 3203020.336
Cd53CD53 antigen125080.342
Cd48CD48 antigen125060.346
FybFYN binding protein238800.352
Ccl5chemokine (C-C motif) ligand 5203040.357
Fcgr3Fc receptor, IgG, low affinity III141310.365
Loxlysyl oxidase169480.365
Cxcl3chemokinne (C-X-C motif) ligand 33301220.369
C3ar1complement component 3a receptor 1122670.369
Slc11a1solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1181730.374
Cxcr4chemokine (C-X-C motif) receptor 4127670.377
Thbs1thrombospondin 16404410.378
Itgb2integrin beta 2164140.378
Serping1serine (or cysteine) peptidase inhibitor, clade G, member 1122580.381
Cd24aCD24a antigen124840.382
Itgamintegrin alpha M164090.386
Pdgfraplatelet derived growth factor receptor, alpha polypeptide185950.392
Cxcl2chemokine (C-X-C motif) ligand 2203100.392
Il12rb1interleukin 12 receptor, beta 1161610.397
Hba-a2hemoglobin alpha, adult chain 2151220.407
Hba-a1hemoglobin alpha, adult chain 11102570.407
Serpine1serine (or cysteine) peptidase inhibitor, clade E, member 1187870.412
Ikzf1IKAROS family zinc finger 1227780.412
C3complement component 3122660.414
Dcndecorin131790.415
S100a6S100 calcium binding protein A6 (calcyclin)202000.429
Stat1signal transducer and activator of transcription 1208460.434
Psmb8proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)169130.441
Lair1leukocyte-associated Ig-like receptor 1528550.442
Cxcl4chemokine (C-X-C motif) ligand 4567440.443
Il2rginterleukin 2 receptor, gamma chain161860.444
Wisp1WNT1 inducible signaling pathway protein 1224020.444
Rarres2retinoic acid receptor responder (tazarotene induced) 2716600.448
S100a9S100 calcium binding protein A9 (calgranulin B)202020.451
Hcls1hematopoietic cell specific Lyn substrate 1151630.452
Cxcl10chemokine (C-X-C motif) ligand 101000450000.453
LynYamaguchi sarcoma viral (v-yes-1) oncogene homolog6766540.454
Ccr1chemokine (C-C motif) receptor 1127680.455
Klrd1killer cell lectin-like receptor, subfamily D, member 1166430.455
Csf2rbcolony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)129830.456
Selplgselectin, platelet (p-selectin)ligand203450.457
Pltpphospholipid transfer protein188300.457
Serpina1aserine (or cysteine) peptidase inhibitor, clade A, member 1a207000.459
S100a8S100 calcium binding protein A8 (calgranulin A)202010.460
Dock2dedicator of cyto-kinesis 2941760.462
Itgb5integrin beta 5164190.462
Thy1thymus cell antigen 1, theta218380.465
Tlr1toll-like receptor 1218970.466
H2-T23histocompatibility 2, T region locus 231000441900.474
Edg3endothelial differentiation, sphingolipid G-protein-coupled receptor, 3136100.476
Lilrb3leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 31000445310.478
Ctsecathepsin E130340.479
Xdhxanthine dehydrogenase224360.483
Etv5ets variant gene 51041560.484
Nt5Ee5′ nucleotidase, ecto239590.484
SaSh3SAM and SH3 domain containing 3741310.489
Ptger4prostaglandin E receptor 4 (subtype EP4)192190.491
Slasrc-like adaptor204910.492
Bgnbiglycan121110.494
Psmb9proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional peptidase 2)169120.495
Cfbcomplement factor B149620.497
Rac2RAS-related C3 botulinum substrate 2193540.499
Mrc1mannose receptor, C type 1175330.500
Cxcl12chemokine (C-X-C motif) ligand 12203150.500
Dnm2dynamin 2134301.906
Brca1breast cancer 1121891.917
Dock1dedicator of cyto-kinesis 13306621.922
Sox4SRY-box containing gene 4206771.940
Myh2myosin, heavy polypeptide 2, skeletal muscle, adult178821.963
Nfatc2nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2180191.981
Mbpmyelin basic protein171961.986
Scn8asodium channel, voltage-gated, type VIII, alpha202732.019
Lama4laminin, alpha 4167752.021
Rab27aRAB27A, member RAS oncogene family118912.025
Plxna1plexin A1188442.031
Fhl1four and a half LIM domains 1141992.077
Aplp2amyloid beta (A4) precursor-like protein 2118042.113
Gulp1GULP, engulfment adaptor PTB domain containing 1706762.222
Timp2tissue inhibitor of metalloproteinase 2218582.224
Tfrctransferrin receptor220422.967
Cckcholecystokinin124243.347
Figure 8

Tumor stroma interactome.

The interaction network for most of the molecules on the list in Table 1 was built by IPA software (Ingenuity company).

Figure 9

Tumor stroma interactome sub-cellular location.

The sub-cellular distribution of the molecules on the interaction network (Figure 8) was built by IPA software (Ingenuity company).

Tumor stroma interactome.

The interaction network for most of the molecules on the list in Table 1 was built by IPA software (Ingenuity company).

Tumor stroma interactome sub-cellular location.

The sub-cellular distribution of the molecules on the interaction network (Figure 8) was built by IPA software (Ingenuity company). While the tumor cells were originally same before being implanted into annexin A1 ko and wt mice, therefore, the tumor stroma in annexin A1 ko and wt mice exhibited significant differences in the gene expression profiles between the host body with and without annexin A1, although the genes in tumor cells may change their expression levels due to the interaction between tumor cells and the tumor stroma. Annexin A1 is abundant in neutrophils, monocytes, macrophages in wild type animal models [4]. In the annexin A1 null animal model, these non-tumor cells infiltrated into tumor stroma do not express annexin A1, this lack of annexin A1 protein function reflected as the gene expression level changes of several other proteins. This network of changes indicated these important genes/proteins (Table 1) that are interacting with annexin A1 directly or indirectly. The interaction of annexin A1 with these proteins was previously unknown.

Discussion

Through systems biology analysis, we found this list of genes (Table 1) that significantly changed in the tumor stroma that lacked annexin A1. This showed a mechanism that annexin A1 affects tumor development and metastasis through interaction with the various components in the microenvironment surrounding the tumor cells. Literature has also showed that these genes are associated with tumor and/or tumor stroma: IGH-6 (ko/wt = 0.065) with thymic lymphoma and lymphoblastic leukemia [7]–[8], TGFBI (ko/wt = 0.108) with neuroblastoma, lung carcinoma, ovarian and prostate cancers, renal, gastrointestinal and brain tumors, colon cancer [9]–[14], PTPRC (ko/wt = 0.143) with human breast tumor stroma [15], MMP13 (ko/wt = 0.147) with skin tumor stroma [16], CCK (ko/wt = 3.347) with human pancreatic cancer [17], TFRC (ko/wt = 2.967) with colon cancer, human esophageal squamous cell carcinoma, human brain tumors, mouse mammary adenocarcinoma and rodent liver tumor [18]–[22], TIMP2 (ko/wt = 2.224) with human colorectal cancer, human pancreatic carcinoma, human renal cell carcinoma and human squamous cervical carcinoma [23]–[26], BRCA1 (ko/wt = 1.917) with human breast tumor stroma [27]. It is worth noting that TGFBI, as an extracellular matrix protein, has been reported differently either as a tumor suppressor [12], [28] or over-expressed in tumors [13]–[14]. TGFBI was shown to promote metastasis by acting on tumor stroma [14]. Here we showed that TGFBI was under-expressed in tumors from annexin A1 ko mice. In tumors grown on annexin A1 ko mice, the metastasis was reduced [1]. Thus, it suggests that annexin A1 interacts with or otherwise affects TGFBI and this interaction affects the metastatic ability of tumors. In addition, loss of TGFBI can induce resistance to chemotherapeutic agent paclitaxel in ovarian cancer cells [29], while human tumor cells with over-expressed levels of TGFBI showed an increased sensitivity to etoposide, paclitaxel, cisplatin and gemcitabine [10]. Similarly, stroma-derived annexin A1 has been shown to play a role in γ-irradiation-induced T-cell lymphoblastic lymphoma development, with annexin A1 being a candidate resistance gene against γ-radiation exposure [30]. It has been reviewed that the cellular and non-cellular components of the tumor microenvironment contribute to the chemoresistance [31]. Therefore, annexin A1 and TGFBI may be further studied together to elicit a mechanism for drug resistance. Annexin A1 and TGFBI could be important therapy targets to manipulate to improve the efficacy of radio-and chemo-therapies for cancer patients, to reduce resistance to treatments and decrease recurrence of cancer. Protein tyrosine phosphatase gene expression was shown to be up-regulated in stromal fibroblasts from human breast tumors [15], while our study showed PTPRC down-regulated in tumor stroma without annexin A1 (Table 1), this suggests that inhibiting annexin A1 may disrupt tumor stroma to hamper tumor progression via decreasing expression level of protein tyrosine phosphatase. MMP13 was shown to promote angiogenesis [16], which is consistent with the finding in this study of down-regulated MMP13 expression (Table 1) and impaired tumor growth and angiogenesis in tumors on annexin A1 knockout mice [1]. The role of endogenous cholecystokinin (CCK) in human pancreatic cancer is not clear. The pancreatic cancer cells produced both CCK and gastrin, however the CCK level was lower than the gastrin. It seemed gastrin played a more dominant role than CCK in stimulating tumor growth. While down-regulation of gastrin inhibited growth of pancreatic tumor, change in the CCK level did not affect the tumor growth [17]. Here we showed a huge increase of CCK mRNA expression in tumors from annexin A1 ko mice, the further study of interaction of annexin A1 and CCK will shed light on understanding the role of CCK in human cancers. Also, this study showed a possible interaction between annexin A1 and BRCA1. It has been shown that in the breast cancers containing mutated BRCA1, a common breast cancer susceptibility gene, changes in the tumor stroma facilitate the malignant transformation of the tumor cells [32]. BRCA1 is also believed to be a regulator in mammary stem cell differentiation and associated with cancer stem cells. One of the identified markers for selection of human stem cells and cancer stem cells is aldehyde dehydrogenase 1 (ALDH1), however, the exact function of ALDH1 in stem cells is still mostly unknown. ALDH1 expression is significantly increased in both tumor cells and tumor stroma in breast cancers carrying BRCA1 mutations [33]. The cancer stem cells possess tumor initiating capacity and therapy resistance. Therefore, consistent with the above mentioned annexin A1 being candidate resistance gene, an association between annexin A1 and stem cells and cancer stem cells is strongly possible and worth further investigation to help understand the exact functions of stem cell markers. Breakdown of immune system process category into its subcategories. (A) Immune system process. (B1) Immune response. (B2) Leukocyte activation. (B3) Immune system development. (C1) Lymphocyte activation. (C2) Myeloid leukocyte activation. (C3) Regulation of leukocyte activation. (C4) Hemopoietic or lymphoid organ development. (D) Hemopoiesis. (E) Leukocyte differentiation. (F) Lymphocyte differentiation. Mining down in Gene Ontology structural networks of hierarchial tree of categories of biological process, the top level category, immune system process, labeled (A), was further mining down levels by levels into its subcategories with all biological processes in each category shown here, labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of cell killing category into its subcategories. (A) Cell killing. (B) Leukocyte mediated cytotoxicity. (C) T cell mediated cytotoxicity. (D) Regulation of T cell mediated cytotoxicity. Similarly as Figure S1, the top level category, cell killing, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of biological adhesion category into its subcategories. (A) Biological adhesion. (B) Cell adhesion. (C1) Cell-cell adhesion. (C2) Cell-substrate adhesion. (C3) Regulation of cell adhesion. (C4) Positive regulation of cell adhesion. (C5) Negative regulation of cell adhesion. (D1) Leukocyte adhesion. (D2) Regulation of cell-substrate adhesion. (D3) Regulation of cell-cell adhesion. (D4) Regulation of cell adhesion mediated by integrin. (E1) Positive regulation of cell adhesion mediated by integrin. (E2) Regulation of cell-cell adhesion mediated by integrin. Similarly as Figure S1, the top level category, biological adhesion, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of multicellular organismal process category into its subcategories. (A) Multicellular organismal process. (B1) Cytokine production. (B2) System process. (B3) Multicellular organismal development. (B4) Tissue remodeling. (B5) Multicellular organismal homeostasis. (B6) Regulation of body fluid levels. (B7) Regulation of multicellular organismal process. (C1) Tumor necrosis factor production. (C2) System development. (C3) Negative regulation of tissue remodeling. (C4) Regulation of tissue remodeling. (C5) Regulation of angiogenesis. (D) Regulation of tumor necrosis factor production. (E) Regulation of tumor necrosis factor biosynthetic process. Similarly as Figure S1, the top level category, multicellular organismal process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of developmental process category into its subcategories. (A) Developmental process. (B1) Multicellular organismal development. (B2) Anatomical structure morphogenesis. (B3) Anatomical structure formation. (B4) Anatomical structure development. (B5) Cellular developmental process. (B6) Regulation of developmental process. (B7) Negative regulation of developmental process. (B8) Positive regulation of developmental process. (C) Positive regulation of programmed cell death. (D1) Induction of programmed cell death. (D2) Positive Regulation of apoptosis. (E1) Induction of apoptosis. (E2) Positive regulation of lymphocyte apoptosis. (F1) Induction of apoptosis by extracellular signals. (F2) Induction of apoptosis by intracellular signals. Similarly as Figure S1, the top level category, developmental process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of locomotion category into its subcategories. (A) Locomotion. (B1) Taxis. (B2) Regulation of locomotion. (B3) Cell motility. (C) Chemotaxis. (D) Cell chemotaxis. (E) Leukocyte chemotaxis. Similarly as Figure S1, the top level category, locomotion, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of cellular process category into its subcategories. (A) Cellular process. (B1) Cell activation. (B2) Cell motion. (B3) Cell communication. (B4) Cell adhesion. (B5) Cell proliferation. (B6) Cellular component organization. (B7) Cellular developmental process. (C1) Mononuclear cell proliferation. (C2) Cell differentiation. (D1) Lymphocyte proliferation. (D2) Leukocyte differentiation. (E) Myeloid leukocyte differentiation. Similarly as Figure S1, the top level category, cellular process, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file. Breakdown of response to stimulus category into its subcategories. (A) Response to stimulus. (B1) Response to external stimulus. (B2) Response to stress. (C1) Defense response. (C2) Response to wounding. (C3) Taxis. (D1) Inflammatory response. (D2) Chemotaxis. (E) Acute inflammatory response. (F) Activation of plasma proteins during acute inflammatory response. (G) Complement activation. Similarly as Figure S1, the top level category, response to stimulus, labeled (A), was further mining down levels by levels into its subcategories labeled alphabetically with each letter for each down level and for each level, representative categories were further broken down into all its subcategories shown here. (PPT) Click here for additional data file.
  32 in total

1.  Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.

Authors:  S R Bramhall; J P Neoptolemos; G W Stamp; N R Lemoine
Journal:  J Pathol       Date:  1997-07       Impact factor: 7.996

2.  Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.

Authors:  Sokbom Kang; Seung Myung Dong; Noh-Hyun Park
Journal:  Gynecol Oncol       Date:  2010-04-24       Impact factor: 5.482

3.  In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.

Authors:  Venugopal Bhuvarahamurthy; Glen O Kristiansen; Manfred Johannsen; Stefan A Loening; Dietmar Schnorr; Klaus Jung; Andrea Staack
Journal:  Oncol Rep       Date:  2006-05       Impact factor: 3.906

Review 4.  Therapeutic targeting of tumor-stroma interactions.

Authors:  Stephen Hiscox; Peter Barrett-Lee; Robert I Nicholson
Journal:  Expert Opin Ther Targets       Date:  2011-03-10       Impact factor: 6.902

5.  Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.

Authors:  M Nakao; J W Janssen; T Flohr; C R Bartram
Journal:  Cancer Res       Date:  2000-06-15       Impact factor: 12.701

6.  Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma.

Authors:  Talvensaari-Mattila Anne; Turpeenniemi-Hujanen Taina
Journal:  Obstet Gynecol Int       Date:  2010-06-29

7.  TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Authors:  Marta Irigoyen; María J Pajares; Jackeline Agorreta; Mariano Ponz-Sarvisé; Elisabeth Salvo; María D Lozano; Ruben Pío; Ignacio Gil-Bazo; Ana Rouzaut
Journal:  Mol Cancer       Date:  2010-05-28       Impact factor: 27.401

Review 8.  Tumor stroma as a target in cancer.

Authors:  F Ahmed; J C Steele; J M J Herbert; N M Steven; R Bicknell
Journal:  Curr Cancer Drug Targets       Date:  2008-09       Impact factor: 3.428

Review 9.  Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.

Authors:  Mauro Perretti; Fulvio D'Acquisto
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

10.  Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer.

Authors:  Marise R Heerma van Voss; Petra van der Groep; Joost Bart; Elsken van der Wall; Paul J van Diest
Journal:  Cell Oncol (Dordr)       Date:  2011-02-19       Impact factor: 6.730

View more
  1 in total

1.  Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.

Authors:  WenBo Wu; GaoZhen Jia; Lei Chen; HaiTao Liu; ShuJie Xia
Journal:  Front Genet       Date:  2021-08-13       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.